Back to Gene
BTK gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

BTK gene

The BTK gene provides instructions for making Bruton tyrosine kinase, a protein essential for the development and maturation of B cells.

Normal Function

The BTK gene provides instructions for making a protein called Bruton tyrosine kinase (BTK), which is essential for the development and maturation of B cells. B cells are specialized white blood cells that help protect the body against infection. These cells can mature into cells that produce special proteins called antibodies or immunoglobulins. Antibodies attach to specific foreign particles and germs, marking them for destruction. The BTK protein transmits important chemical signals that instruct B cells to mature and produce antibodies.

Health Conditions Related to Genetic Changes

Isolated growth hormone deficiency

A few mutations in the BTK gene have been found to cause isolated growth hormone deficiency type III, a condition characterized by slow growth, short stature, and a weakened immune system. Mutations that cause this condition lead to production of a nonfunctional version of the BTK protein. People with isolated growth hormone deficiency are prone to infections because they produce very few B cells and have a shortage of antibodies (agammaglobulinemia). A lack of the BTK protein is likely responsible for the immune system symptoms, but how a shortage of BTK protein causes short stature in affected individuals is unclear.

X-linked agammaglobulinemia

More than 600 different mutations in the BTK gene have been found to cause X-linked agammaglobulinemia (XLA). Most of these mutations result in the absence of the BTK protein. Other mutations change a single protein building block (amino acid), which probably leads to the production of an abnormal BTK protein that is quickly broken down in the cell. The absence of functional BTK protein blocks B cell development and leads to a lack of antibodies, causing an increased susceptibility to infections in people with XLA.

Some people with XLA have large DNA deletions that remove one end of the BTK gene and all of a neighboring gene known as TIMM8A. Mutations in TIMM8A cause deafness-dystonia-optic neuronopathy (DDON) syndrome. Individuals with large DNA deletions that include the BTK gene and the TIMM8A gene have the signs and symptoms of both XLA and DDON syndrome.

Frequently Asked Questions

Newborns are protected during their first 4 to 6 months of life by maternal immunoglobulin G (IgG) antibodies that cross the placenta during pregnancy. As maternal antibody levels naturally decline and the infant cannot produce their own B cells or antibodies due to the BTK mutation, recurrent bacterial and enteroviral infections begin to occur, typically between 6 and 12 months of age.
The primary treatment is lifelong immunoglobulin replacement therapy administered either intravenously (IVIG) every three to four weeks or subcutaneously (SCIG) weekly or biweekly. This replaces the missing antibodies, protects against recurrent sinopulmonary and systemic infections, and significantly reduces the risk of chronic lung damage such as bronchiectasis.
Live attenuated vaccines—including oral polio, rotavirus, MMR, and live influenza—are strictly contraindicated because the lack of an effective humoral immune response can allow vaccine strains to cause chronic or life-threatening systemic infection. Inactivated vaccines are safe to administer, although they will elicit little to no protective antibody response due to the underlying absence of mature B cells.
X-linked agammaglobulinemia is an X-linked recessive condition that primarily affects males. Females with one mutated copy are generally asymptomatic carriers due to non-random X-chromosome inactivation in the B-cell lineage. A female carrier has a 50 percent chance in each pregnancy of passing the variant to a son, who will be affected, or to a daughter, who will also be a carrier.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab